Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD151-CD19 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Galapagos
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**CD151-CD19 CAR-T cells** are an investigational, lentivirally engineered anti-CD19 CAR-T cell product in which healthy-donor T cells co-express the tetraspanin CD151 and an anti-CD19 chimeric antigen receptor containing CD28 costimulatory and CD3ζ signaling domains. The construct is designed to retain CD19-directed cytotoxicity while enhancing antigen-dependent CAR-T-cell proliferation through CD151 overexpression. In vitro testing reported comparable cytotoxicity, activation, cytokine production, manufacturing expansion, and CAR expression versus conventional CD19 CAR-T cells, with greater proliferation after antigen engagement and no antigen-independent expansion. The program was reported by Kite as a preclinical in vitro CAR-T engineering approach; no clinical indication or clinical-stage trial was identified.
- Other names
- CD151 overexpressing CD19 CAR-T cellsCD-151 overexpressing CD19 CAR-T cellsCD 151 overexpressing CD19 CAR-T cellsCD151-CD19 CAR-T cellsCD-151-CD19 CAR-T cellsCD 151-CD19 CAR-T cells
02
Targets
CD151 (CD151 molecule (Raph blood group))CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on CD151-CD19 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD151-CD19 CAR-T cells.